Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.090 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 9.090
Bid (Size) 8.580 (5,000)
Ask (Size) 9.220 (100)
Prev. Close 9.090
Today's Range 9.090 - 9.090
52wk Range 7.730 - 11.80
Shares Outstanding 45,047,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prothena (NASDAQ:PRTA) Beats EPS but Misses Revenue in Mixed Q2 2026 Results ↗
Via Chartmill
News headline image
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire

Performance

YTD
-1.2%
-1.2%
1 Month
+6.2%
+6.2%
3 Month
-8.9%
-8.9%
6 Month
+5.2%
+5.2%
1 Year
+6.2%
+6.2%

More News

Read More
News headline image
Prothena to Report Second Quarter 2026 Financial Results on August 6
From Prothena Corporation plc
Via Business Wire
Prothena (NASDAQ:PRTA) Smashes Q1 Estimates on $50 Million Milestone Payment, Shares Steady ↗
Via Chartmill
News headline image
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report First Quarter 2026 Financial Results on May 7
From Prothena Corporation plc
Via Business Wire
Prothena Corporation (NASDAQ:PRTA) Reports Q4 2025 Revenue Miss, Highlights Pipeline Progress and 2026 Cash Guidance ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Leadership Team Updates
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces up to $100 Million Share Repurchase Plan
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Board of Directors Update
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗
Via Benzinga
News headline image
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Corp PLC (NASDAQ:PRTA) Reports Q3 2025 Earnings and Key Pipeline Milestones ↗
Via Chartmill
News headline image
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Third Quarter 2025 Financial Results on November 6
From Prothena Corporation plc
Via Business Wire
News headline image
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings) ↗
Via Benzinga
News headline image
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire

Frequently Asked Questions

Is Prothena Corporation plc - Ordinary Shares publicly traded?
Yes, Prothena Corporation plc - Ordinary Shares is publicly traded.
What exchange does Prothena Corporation plc - Ordinary Shares trade on?
Prothena Corporation plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Prothena Corporation plc - Ordinary Shares?
The ticker symbol for Prothena Corporation plc - Ordinary Shares is PRTA on the Nasdaq Stock Market
What is the current price of Prothena Corporation plc - Ordinary Shares?
The current price of Prothena Corporation plc - Ordinary Shares is 9.090
When was Prothena Corporation plc - Ordinary Shares last traded?
The last trade of Prothena Corporation plc - Ordinary Shares was at 08/27/26 04:00 PM ET
What is the market capitalization of Prothena Corporation plc - Ordinary Shares?
The market capitalization of Prothena Corporation plc - Ordinary Shares is 409.48M
How many shares of Prothena Corporation plc - Ordinary Shares are outstanding?
Prothena Corporation plc - Ordinary Shares has 409M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.